Krystian Mączka

Krystian Mączka

Auto-generated profile, based on publicly available information

Krystian Mączka

University Clinical Hospital in Wroclaw, Borowska 213, 50-556 Wrocław, Poland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2025 in International Urology and Nephrology
Verified
Journal Article
Open access
PDF file
Jakub KarwackiJakub Karwacki
Jakub Karwacki
AMAgnieszka Mioskowska
Agnieszka Mioskowska
PTPaulina Tomecka
Paulina Tomecka
KMKrystian Mączka
Krystian Mączka
AGAdam Gurwin
Adam Gurwin
Bartosz MałkiewiczBartosz Małkiewicz
Bartosz Małkiewicz
Purpose This study aimed to evaluate the impact of metastatic lymph nodes (LNs) outside the extended pelvic lymph node dissection (ePLND) template on oncological outcomes, staging, grading, and concomitant parameters in prostate cancer (PCa) patients undergoing radical prostatectomy (RP). Methods Data from 860 patients with histologically confirmed, non-metastatic PCa who underwent RP between 2012 and 2022 were retrospectively analyzed. All specimens underwent detailed histopathological examination. Preoperative and postoperative clinicopathological data were collected and analyzed. Subgroup associations were evaluated using the Mann–Whitney U test and the Kruskal–Wallis test. Kendall’s tau-b coefficient was employed to evaluate the association between two variables. All tests were performed using a two-tailed approach, with a p value of less than 0.05 considered statistically significant for differences between groups. Kaplan–Meier and Cox regression analyses assessed biochemical recurrence (BCR)-free survival based on lymph node invasion (LNI) (pN0 vs. pN1) and the presence of metastatic LNs outside the ePLND template. Results Of the 860 patients, 613 underwent modified-ePLND. Among them, 122 (19.9%) were pN1, with 22 patients (18%) having metastatic LNs located outside the classical ePLND template. Patients with LNs beyond the ePLND template exhibited higher clinical T stages (p = 0.016) and a greater percentage of positive biopsy cores (p = 0.008). However, no correlation was observed with Gleason Grading Group (p = 0.491). Kaplan–Meier analysis showed that pN1 patients had higher BCR rates compared to pN0 patients, but this difference did not reach statistical significance (p = 0.174). Similarly, patients with metastatic LNs outside the ePLND template demonstrated a trend toward increased BCR risk, though this was not statistically significant (p = 0.140). Conclusion Metastatic LNs beyond the ePLND template correlate with more advanced tumor staging in PCa. However, they show no association with tumor grading. Their influence on BCR remains inconclusive, likely due to the small number of patients included in the BCR-associated analyses. Extended lymphadenectomy may enhance staging accuracy but must be weighed against the potential for increased surgical morbidity.

5 January 2023 in Journal of Ultrasonography
Verified
Journal Article
Closed access
MTMaciej Trzciniecki
Maciej Trzciniecki
WBWiktor Bursiewicz
Wiktor Bursiewicz
MTMonika Trzciniecka
Monika Trzciniecka
KMKrystian Mączka
Krystian Mączka
MLMikołaj Legieć
Mikołaj Legieć
PKPaweł Kowal
Paweł Kowal
Renal cell carcinoma is a common disease, and clear cell renal cell carcinoma is the most common histological type. Renal cell carcinoma has a tendency to infiltrate the venous system including the inferior vena cava and the right atrium of the heart. We present the cases of two patients with renal cell carcinoma with stage IV tumor thrombus according to the Mayo classification, who underwent surgery under transesophageal echocardiography guidance. Apart from standard imaging methods used in renal cancer with tumor thrombus reaching the right atrium of the heart, we consider transesophageal echocardiography to be a very useful tool in the diagnostic work-up, patient monitoring, and selection of appropriate surgical technique.

6 July 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
KMKrystian Mączka
Krystian Mączka
KKKarol Kazimierczak
Karol Kazimierczak
AWAmadea Wrzesińska
Amadea Wrzesińska
DGDaniel Grobecki
Daniel Grobecki
MKMateusz Korowacki
Mateusz Korowacki
MPMichał Przybylski
Michał Przybylski
Background: Supplementation with inorganic nitrates (NO3-) and caffeine (CAF) is a common practice in competitive sports. Despite the documented ergogenic effects of both substances, their potential synergy across different exercise models remains a subject of scientific debate. Objective: The aim of this systematic review was to evaluate and compare the impact of isolated and combined CAF and NO3- supplementation on mechanical and physiological parameters in resistance and endurance tests. Methods: The review was conducted according to PRISMA guidelines by searching PubMed and Scopus databases. Experimental studies on healthy adults, published primarily between 2021 and 2026, regarding the effects of supplementation on power, strength, muscular endurance, and aerobic capacity were analyzed. Results: Nitrates improved muscular endurance 65% one repetition maximum (65% 1RM) and fatigue resistance in sprints without affecting power at maximum loads (1RM). Caffeine increased power at 75–100% 1RM (primarily in the lower body) and the number of repetitions at 65% 1RM. Co-supplementation (CAF + NO3-) showed a significant additive effect only in muscular endurance tasks. No synergy was found in time trials (TT) or cardiorespiratory parameters (VO2, heart rate). Conclusion: The combination of caffeine and nitrates is a highly effective strategy for high-volume anaerobic efforts but offers no additional benefits in traditional endurance tests. Optimizing results requires individualizing CAF dosage based on genotype and maintaining proper timing for nitrate intake.

8 July 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
AWAmadea Wrzesinska
Amadea Wrzesinska
MKMateusz Korowacki
Mateusz Korowacki
IRIga Rusin
Iga Rusin
KKKarol Kazimierczak
Karol Kazimierczak
KMKrystian Mączka
Krystian Mączka
DGDaniel Grobecki
Daniel Grobecki
Introduction: Achilles tendon tendinopathy is a common degenerative disorder causing pain and functional limitation. Despite numerous treatment options, optimal management remains a clinical challenge. Aim: To summarize current evidence on the pathophysiology, diagnosis, conservative treatment, modern adjunctive therapies, and surgical management of Achilles tendon tendinopathy . Materials and methods: This narrative review is based on scientific literature, including guidelines, systematic reviews, and clinical studies. Particular attention was paid to diagnostic methods, progressive rehabilitation, extracorporeal shockwave therapy (ESWT), injections (PRP, hyaluronic acid, high-volume), fenestration, stem cells, and surgery. Results: Diagnosis is primarily clinical, with ultrasound and MRI reserved for unclear or resistant cases. Conservative treatment is the first-line approach, focusing on load management and structured rehabilitation (e.g., the Alfredson protocol). Modern adjunctive therapies and injections may provide benefits, though evidence quality varies. Surgical treatment is reserved for persistent cases failing conservative therapy. Conclusions: Effective management requires an individualized, multidisciplinary approach centered on patient education, load modification, and evidence-based rehabilitation. Biological and minimally invasive therapies serve as adjuncts, but further high-quality studies are needed

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JDJakub Dyczko
Jakub Dyczko
FKFilip Kruczek
Filip Kruczek
KMKrystian Mączka
Krystian Mączka
DGDaniel Grobecki
Daniel Grobecki
BŚBartosz Świrad
Bartosz Świrad
MPMichał Przybylski
Michał Przybylski
Background. Familial hypercholesterolemia (FH) is a common autosomal dominant genetic disorder associated with premature atherosclerotic cardiovascular disease. Despite established international guidelines, FH remains substantially underdiagnosed, particularly in young adults. Aim. This narrative review summarizes current evidence on diagnostic challenges and barriers to guideline implementation in this population. Methods. A narrative literature review was conducted using PubMed/MEDLINE, Scopus, and Web of Science databases. The review focused on evidence regarding FH epidemiology, diagnostic approaches, genetic testing, cascade screening, treatment strategies, and implementation gaps in young adults. Results. Registry data indicate that the median age of FH diagnosis is 44.4 years, suggesting delayed identification and prolonged exposure to elevated low-density lipoprotein cholesterol levels during early adulthood. In young adults, diagnosis is often limited by the absence of overt clinical signs, reducing the utility of clinical scoring systems such as the Dutch Lipid Clinic Network criteria. As a result, diagnosis relies primarily on lipid measurements, family history, and genetic testing. However, genetic testing and cascade screening remain underutilized in routine clinical practice. Conclusions. A persistent gap exists between guideline recommendations and real-world management of FH. Delayed diagnosis and suboptimal implementation of treatment strategies contribute to inadequate cardiovascular risk reduction in young adults. Improving early detection through enhanced use of genetic testing, optimization of cascade screening, and timely initiation of lipid-lowering therapy may reduce cumulative LDL-C exposure and improve long-term cardiovascular outcomes.

7 September 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MKMateusz Korowacki
Mateusz Korowacki
AWAmadea Wrzesińska
Amadea Wrzesińska
IRIga Rusin
Iga Rusin
KMKrystian Mączka
Krystian Mączka
DGDaniel Grobecki
Daniel Grobecki
BŚBartosz Świrad
Bartosz Świrad
Schizophrenia and Alzheimer's disease are serious neurological disorders that, despite their different clinical pictures, show significant connections at the neuroanatomical, genetic, and functional levels. Research suggests that patients with schizophrenia have an increased risk of developing dementia, including Alzheimer's disease. Neuroimaging analyses indicate similarities in white matter damage, reduction in the volume of the hippocampus and prefrontal cortex, suggesting common neurodegenerative mechanisms that lead to cognitive impairment and behavioral changes. Genetic studies show a partial overlap in the polygenic risk of schizophrenia and Alzheimer's disease, especially in the genes related to neurotransmission, neuroinflammation, and synaptic function. Furthermore, the occurrence of psychotic symptoms in Alzheimer's disease may have different mechanisms than in schizophrenia, which significantly affects the effectiveness of therapy. Second-generation drugs, such as risperidone or aripiprazole, exhibit varying effectiveness depending on the neuropathological basis of psychosis, which underscores the need for individualized therapy and the search for new treatment strategies. New research directions focus on identifying neurodegenerative biomarkers and innovative therapeutic methods. There is particular hope for anti-PD-1 immunotherapy, which can modulate the inflammatory response and slow the progression of Alzheimer's disease. Additionally, the development of liquid biomarkers and advanced neuroimaging studies may enable earlier detection of pathological changes, which will allow for more effective therapeutic intervention.